Eton Pharmaceuticals Inc (ETON) - Total Liabilities
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has total liabilities worth $67.09 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ETON shareholders equity momentum to track the company's year-over-year net asset growth rate.
Eton Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Eton Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.
Eton Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Danya Cebus
TA:DNYA
|
Israel | ILA2.55 Billion |
|
Huadian Heavy Industries Co
SHG:601226
|
China | CN¥6.08 Billion |
|
Focus Lightings Tech Co Ltd
SHE:300708
|
China | CN¥2.22 Billion |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
Thailand | ฿3.43 Billion |
|
Hbt Financial Inc
NASDAQ:HBT
|
USA | $6.03 Billion |
|
BP PLC
LSE:BP
|
UK | GBX204.53 Billion |
|
Jiangxi Guotai Civilian
SHG:603977
|
China | CN¥2.43 Billion |
|
Invisio Communications AB
ST:IVSO
|
Sweden | Skr432.90 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Eton Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ETON stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eton Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Eton Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.96 Million | +27.59% |
| 2024-12-31 | $51.70 Million | +217.87% |
| 2023-12-31 | $16.26 Million | +36.07% |
| 2022-12-31 | $11.95 Million | +21.53% |
| 2021-12-31 | $9.84 Million | -7.70% |
| 2020-12-31 | $10.66 Million | +63.39% |
| 2019-12-31 | $6.52 Million | +222.23% |
| 2018-12-31 | $2.02 Million | +54.15% |
| 2017-12-31 | $1.31 Million | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more